CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
All of the shares were offered by CG Oncology.
- All of the shares were offered by CG Oncology.
- The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $437.0 million.
- CG Oncology’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “CGON.”
Morgan Stanley, Goldman Sachs & Co. LLC and Cantor acted as joint book-running managers for the offering. - Registration statements relating to the offering have been filed with the Securities and Exchange Commission (SEC) and became effective on January 24, 2024.